According to The Verge, Withings has announced a new partnership with Abbott during CES 2026. The key move is that users of Abbott’s Lingo over-the-counter continuous glucose monitor (CGM) will be able to view their glucose data directly within the Withings app starting in the first quarter of the year. Furthermore, Withings users in the US will be able to purchase Lingo CGMs directly from the Withings website, where a pack of two sensors will cost $89. This follows Withings’ earlier CES reveal of a new “longevity station” smart scale focused on metabolic and cardiovascular health. The deal also mirrors a similar partnership between Oura and Dexcom, another major player in the OTC CGM space.
The Data Convergence Play
Here’s the thing: this isn’t really about hardware. It’s about data aggregation. Withings is building a centralized dashboard for a very specific type of user—someone who’s non-diabetic but is deeply interested in “biohacking” or “longevity.” By pulling in glucose data from Abbott‘s Lingo, Withings can now offer a more complete picture alongside its own metrics like weight, body composition, and heart rate. It’s a smart, asset-light way to expand their platform’s capabilities without having to develop their own CGM, which is a regulatory and technical minefield. Basically, they’re turning their app into a command center for the health-obsessed.
Mirroring the Competition
But let’s be real, this feels a bit like catching up. The Verge points out this mirrors Oura’s deal with Dexcom. The smart ring and smart scale companies are essentially racing to the same finish line: becoming the primary, trusted health data hub on your phone. For Oura and Withings, CGMs are the missing puzzle piece for metabolic insight. So this partnership was almost inevitable. It begs the question: is this about offering unique value, or is it just checking a necessary box to stay competitive in the wellness tech arms race? I think it’s a bit of both. You can’t be a serious longevity platform in 2026 without glucose data.
The OTC Wellness Market Heats Up
Now, the real interesting shift here is the continued mainstreaming of CGMs for people without diabetes. Abbott’s Lingo and Dexcom’s Stelo are betting big that millions of people will pay out-of-pocket to monitor their glucose spikes out of sheer curiosity or optimization zeal. Partnering with Withings gives Abbott a direct sales channel to a pre-qualified, health-focused audience. And for the user, the promise is simple: see how your sleep (from Withings) correlates with your glucose levels (from Abbott) all in one place. It’s a compelling narrative, but the long-term utility for the average healthy person is still unproven. Will people really keep paying $45 per sensor every two weeks after the novelty wears off? That’s the billion-dollar question.
